Shares of Eli Lilly & Co. rose 3.38% to $1,062.19 Monday, on what proved to be an all-around grim trading session for the ...

Eli Lilly could extend its lead in its core therapeutic area with the launch of two new products next year. The company also ...

Discover why Eli Lilly's stock downturn may present new opportunities. Learn about valuation, Zepbound pricing, and 2026 ...

In an added benefit, more than one in eight people taking the highest dose of Retratrutide were completely free of arthritic ...

Eli Lilly's shares may appear expensive at first glance, but a closer look reveals a different story. The company's outlook ...

Eli Lilly is investing $6B in a Huntsville, Ala., plant to make weight-loss and other medicines. Here’s what we know about ...

Notably, the Huntsville site will be among those that will manufacture orforglipron, Lilly’s first oral, small molecule GLP-1 ...

Expanding Lilly’s U.S. manufacturing presence in Alabama will boost the Huntsville economy. For every dollar Lilly invests ...

Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...

Eli Lilly will cut prices for its weight loss drug Zepbound, with single-dose vials now available for $299 per month through ...

Major pharmaceutical manufacturer Eli Lilly and Company is building a $6 billion plant in the Tennessee Valley.

Step aside, semaglutide—retatrutide is showing the most impressive weight loss results of any obesity drug to date.